Impact of the Blood Culture Technique on the Diagnosis of Infective Endocarditis
Launched by CENTRAL HOSPITAL, NANCY, FRANCE · May 12, 2017
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients older than 18 years
- • Suspected endocarditis: Patients with Duke-Li-ESC 2015 classification as a major morphological criterion or at least two minor criteria, other than a microbiological criterion, will be considered suspicious of infectious endocarditis.
- • Not objecting to their inclusion in the study after delivery and explanation of the information form.
- • Absence of microbiological documentation sought or available at the time of inclusion (a patient having already had negative blood cultures or being identified during the screening can be included).
- Exclusion Criteria:
- • Antibiotherapy adapted to a situation of endocarditis, introduced more than 24 hours or stopped for less than 7 days in case of therapeutic window.
- • Any previous antibiotic therapy in the 7 days preceding the inclusion leading to an improvement in the clinical symptomatology.
- • State of consciousness not allowing loyal information.
About Central Hospital, Nancy, France
Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Reims, , France
Besancon, , France
Belfort, , France
Dijon, , France
Nancy, , France
Rennes, , France
Strasbourg, , France
Patients applied
Trial Officials
François Goehringer, MD
Principal Investigator
Centre Hospitalier Universitaire de Nancy, Nancy, France
Xavier Duval, MD PhD
Study Chair
APHP, Hôpital Bichat Claude Bernard, Paris, France.
Christine Selton-Suty, MD
Study Chair
Centre Hospitalier Universitaire de Nancy, Nancy, France
Nejla Aissa, MD
Study Chair
Centre Hospitalier Universitaire de Nancy, Nancy, France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials